https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Hematology
Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria

Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria

Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults. The Ultomiris EU approval is for patients with PNH with hemolysis with clinical symptoms that indicate high disease activity, and also for adult patients […]

Takeda bags ADCETRIS EC approval for CD30+ Stage IV Hodgkin lymphoma

ADCETRIS EC approval : The European Commission (EC) has expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to cover treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adult patients. ADCETRIS is an antibody-drug conjugate (ADC) that targets CD30, which is a defining marker of […]

Continue reading …
Ablynx wins Cablivi FDA approval for rare blood clotting disorder

Cablivi FDA approval : Belgian biopharma company Ablynx has bagged approval from the US Food and Drug Administration (FDA) for its anti-vWF nanobody Cablivi (caplacizumab-yhdp) injection in combination with plasma exchange and immunosuppressive therapy for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). According to the FDA, aTTP is a rare blood clotting disorder in […]

Continue reading …
Spectrum offloads seven hematology/oncology drugs to Acrotech in $300m deal

US biopharma company Spectrum Pharmaceuticals has agreed to offload seven of its FDA-approved hematology/oncology drugs to Acrotech Biopharma, a subsidiary of Aurobindo Pharma USA, in a deal worth around $300 million. The decision to sell the drugs has been taken to focus on new and innovative therapies for cancer patients, said Spectrum Pharmaceuticals. The seven […]

Continue reading …
Bayer hematology drug Jivi scores FDA approval for hemophilia A treatment

Jivi FDA approval : German pharma company Bayer has bagged the US Food and Drug Administration (FDA) approval for its recombinant factor VIII (rFVIII) replacement therapy Jivi (BAY94-9027) as routine preventative treatment of hemophilia A. The approval of the Bayer hematology drug for hemophilia A treatment covers both adults and adolescents, aged 12 years or […]

Continue reading …